Aspartame and Risk of Cancer: A Meta-analytic Review

Archives of Environmental and Occupational Health

Volumn 70, Issue 3, 2015, Pages 133-141

  Mallikarjun, Sreekanth ^a   Sieburth, Rebecca McNeill ^b  

^a Stony Brook University   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aspartame; cancer; meta analysis

Indexed keywords

ASPARTAME; SWEETENING AGENT;

BIOASSAY; CANCER RISK; CARCINOGENICITY; EFFECT SIZE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; CHEMICALLY INDUCED; HUMAN; META ANALYSIS; NEOPLASMS; RISK ASSESSMENT;

RODENTIA;

ASPARTAME; HUMANS; NEOPLASMS; RISK ASSESSMENT; SWEETENING AGENTS;

EID: 84929731672     PISSN: 19338244     EISSN: 21544700     Source Type: Journal    
DOI: 10.1080/19338244.2013.828674     Document Type: Review

References (41)

1. Food and Drug Administration. Aspartame: commissioner's final decision. Docket no. 75F-0355. Fed Regist. 1981;46:38285-38308.
2. European Food Safety Authority. Opinion of the Scientific Panel AFC related to a new long-term carcinogenicity study on aspartame. Available at: http://www.efsa.europa.eu/en/science/afc/ afc opinions/1471.html EFSA EU, afc opinions, 1471 en. Published 2006. Accessed October 17, 2012.
3. Fry J. The world market for intense sweeteners. World Rev Nutr Diet. 1999;85:201-211.
4. Aspartame Information Center. Aspartame Information Center homepage. Available at: http://www.aspartame.org. Published 2005. Accessed November 27, 2012.
5. Mead MN. Sour finding on popular sweetener: increases cancer incidence associated with low-dose aspartame intake. Environ Health Perspect. 2006;114:A176.
6. Huff J., Ladou L. Aspartame bioassay findings portend human cancer hazards. Int J Occup Environ Health. 2007;4:446-448.
7. ∗Soffiriti M, Belpoggi F, Esposti DD, Lambertini L, Tibaldi E, Lauriola M. First carcinogenic effects of aspartame administered in the feed to Spague-Dawley rats. Environ Health Perspect. 2006;114:379-385.
8. Huff J. Long-term chemical carcinogenesis bioassays predict human cancer hazards issues, controversies, and uncertainties. Ann N Y Acad Sci. 1999;895:56-79.
9. ∗Ishii H, Koshimizu T, Usami S, Fujimoto T. Toxicity of aspartame and its diketopiperazine for Wistar rats by dietary administration for 104 weeks. Toxicology. 1981;21:91-94.
10. Hunty ADL, Gibson S, Ashwell M. A review of the effectiveness of aspartame in helping with weight control. Nutr Bull. 2006;31:115-128.
11. Vartanian LR, Schwartz MB, Brownell KD. Effects of soft drink consumption on nutrition and health: a systematic review and metaanalysis. Am J Public Health. 2007;97:667-675.
12. Mattes RD, Shikany JM, Kaiser KA, Allison DB. Nutritively sweetened beverage consumption and body weight: a systematic review and meta-analysis of randomized experiments. Obes Rev. 2011;12:346-365.
13. Malik VS, Popkin BM, Bray GA, Despres JP, Willett WC, Hu FB. Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis. Diabetes Care. 2010;33:2477-2483.
14. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65-94.
15. Rosenthal R. Meta-analytic Procedures for Social Research. Newbury Park, CA: Sage; 1991.
16. Hunter JE, Schmidt FL. Methods of Meta-analysis: Correcting Error and Bias in Research Findings. Newbury Park, CA: Sage Publication; 1990.
17. Sobin LH, Fleming ID, eds. TNM Classification of Malignant Tumors. Chicago, IL: Union International Control of Cancer and the American Joint Committee on Cancer. 1997;80:1803-1804.
18. Lipsey MW, Wilson DB. Practical Meta-analysis. Thousand Oaks, CA: Sage Publications; 2001.
19. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Lawrence Erlbaum Associates; 1988.
20. Borenstein M, Hedges LV, Higgins JPT, Rothstein H. Fixed-effect versus random-effects models. In: Introduction to Meta-analysis. Chichester, United Kingdom: John Wiley & Sons, Ltd.; 2009:77-85.
21. Schmidt FL, Oh IS, Hayes TL. Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol. 2009;62:97-128.
22. Hedges LV. A random effects model for effect sizes. Psychol Bull. 1983;93:388-395.
23. Hedges LV, Olkin I, Statistiker M. Statistical Methods for Metaanalysis. New York: Academic Press; 1985.
24. Higgins JPT, Thompson SG, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
25. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Vol. 5. Chichester, UK: Wiley-Blackwell, 2008: 278.
26. Viechtbauer W. Bias and efficiency of meta-analytic variance estimators in the random-effects model. J Educ Behav Stat. 2005;30:261-293.
27. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-analysis, version 2.0 [computer software]. Englewood, NJ: Biostat; 2005
28. Bax L, Yu LM, Ikeda N, Moons K. A systematic comparison of software dedicated to meta-analysis of causal studies. BMC Med Res Methods. 2007;7:40.
29. Council of Scientific Affairs. Aspartame: a review of safety issues. JAMA. 1985;254:400-402.
30. ∗File E-33. Appendix: Two Year Toxicity Study in the Rat. PT 838H71, submitted by G.D. Searle & Company to the FDA. Administrative Record, Aspartame. Docket No. 75F-0355, FDA, Rockville, Maryland, 1973.
31. ∗File E-34. Two Year Toxicity Study in the Rat. PT 838H71, submitted by G.D. Searle & Company to the FDA. Administrative Record, Aspartame. Docket No. 75F-0355, FDA, Rockville, Maryland, 1973.
32. ∗File E-70. Lifetime Toxicity Study in the Rat. PT 838H72, Final Report, submitted by G.D. Searle & Company to the FDA. Administrative Record, Aspartame. Docket No. 75F-0355, FDA, Rockville, Maryland, 1974.
33. ∗File E-75. 104-Week Toxicity Study in the Mouse. PT 984H73, submitted by G.D. Searle & Company to the FDA. Administrative Record, Aspartame. Docket No. 75F-0355, FDA, Rockville, Maryland, 1974.
34. Molinary SV. Preclinical studies of aspartame in nonprimate animals. In: Stegink LD, Filer LJ, eds. Aspartame Physiology and Biochemistry. New York: Dekker; 1984:289-306.
35. ∗Ishii H. Incidence of brain tumors in rats fed aspartame. Toxicol Lett. 1981;7:433-437.
36. ∗National Toxicology Program (NTP). Toxicology Studies of Aspartame (CAS No. 22839-47-0) in Genetically Modified (FVB Tg.AC Hemizygous) and B6.129 Cdkn2atm1Rdp (N2) Deficient Mice and Carcinogenicity Studies of Aspartame in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Feed Studies). Research Triangle Park, NC: US National Toxicology Program. NTP GMM1, NIH Publication No. 06-4459. Available at: http://ntp.niehs.nih.gov/files/GMM1-Web.pdf. Published 2005. Accessed October 11, 2012.
37. ∗Soffiriti M, Belpoggi F, Tibaldi E, Esposti DD, Lauriola M. Lifespan exposure to low doses of aspartame beginning during prenatal life increases cancer effects in rats. Environ Health Perspect. 2007;115:1293-1297.
38. ∗Soffritti M, Belpoggi F, Manservigi M, et al. Aspartame Administered in Feed, Beginning prenatally through life span, induces cancers of the liver and lung in male Swiss mice. Am J Ind Med. 2010;52:1197-1206.
39. Rosenthal R, Rubin DB. Comparing effect sizes of independent studies. Psychol Bull. 1982;92:500-504.
40. Fleiss JL. Measures of effect sizes for categorical data. In: Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. NewYork: Russell Sage Foundation; 1994:245-260.
41. Overton RC. A comparison of fixed-effects and mixed (randomeffects) models for meta-analyses tests of moderator variable effects. Psychol Methods. 1998;3:354-379.